Previous 10 | Next 10 |
Chiasma (NASDAQ: CHMA ) +21% as Mycapssa successful in late-stage acromegaly study. More news on: Chiasma, Inc., Realogy Holdings Corp., Diffusion Pharmaceuticals Inc., Stocks on the move, Read more ...
Thinly traded Myovant Sciences (NYSE: MYOV ) is up 9% premarket on light volume following its announcement of positive results from a second Phase 3 clinical trial, LIBERTY 2 , evaluating once-daily relugolix in women with uterine fibroids and heavy menstrual bleeding. More ...
Primary efficacy endpoint met with 71.2% response rate (p < 0.0001); women experienced, on average, an 84.3% reduction in menstrual blood loss (p < 0.0001) Achieved six key secondary endpoints including reduction in pain, with a well-tolerated safety profile including low incidence ...
Myovant Sciences (NYSE: MYOV ) will host a conference call tomorrow, July 23, at 8:30 am ET to discuss results from a second Phase 3 clinical trial, LIBERTY 2 , evaluating relugolix combination therapy in women with uterine fibroids and heavy menstrual bleeding. More news on: Myovant Sc...
BRISBANE, Calif. and BASEL, Switzerland, July 22, 2019 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE:MYOV), a clinical-stage healthcare company focused on developing and commercializing innovative therapies for women’s health and prostate cancer, today announced it will hold a webc...
I regard golf as an expensive way of playing marbles ." - G.K. Chesterton Being in London this week, I thought today, we would take an in-depth look at a local developmental firm in today's article. Company Overview: Myovant Sciences ( MYOV ) IPO'd in 2016 and is a United Kingdom-ba...
Digital insights study to include over 20,000 people and evaluate women’s menstrual experiences, including symptoms such as heavy menstrual bleeding and menstrual pain PERIOD. Inc., a Myovant partner and nonprofit dedicated to menstrual equity and destigmatization, contributed to t...
InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi...
InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi...
BRISBANE, California and BASEL, Switzerland, June 04, 2019 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV ), a clinical-stage healthcare company focused on developing and commercializing innovative therapies for women’s health and prostate cancer, today announced that Ly...
News, Short Squeeze, Breakout and More Instantly...
NEW YORK, NY / ACCESSWIRE / October 19, 2023 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Myovant Sciences, Ltd. ("Myovant" or "the Company") (NYSE:MYOV). Investors who purchased Myovant securities are encouraged to obtain additional infor...
Third fiscal quarter 2022 total revenue of $100.2 million ; including net product revenue of $61.4 million Net product revenue from U.S. sales of ORGOVYX ® of $48.7 million in third fiscal quarter 2022, with sequential quarterly demand volume ...
MYOV SPECIAL ALERT: Julie & Holleman Investigates Potential Legal Claims Related to Take-Private Acquisition of Myovant Sciences MYOV SPECIAL ALERT: Julie & Holleman Investigates Potential Legal Claims Related to Take-Private Acquisition of Myovant Sciences PR Newswire ...